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A Preliminary Analysis of Combined Liver Resection
With New Chemotherapy for Synchronous and
Metachronous Colorectal Liver Metastasis
Wilson Wing Chi Ng, Yue Sun Cheung, John Wong, Kit Fai Lee and Paul Bo San Lai, Division of Hepatobiliary
and Pancreatic Surgery, Department of Surgery, The Chinese University of Hong Kong, Hong Kong SAR.
OBJECTIVE: To compare the survival between patients with synchronous and metachronous colorectal
liver metastases after hepatectomy with new generation of perioperative chemotherapy.
METHODS: From October 2002 to January 2008, patients receiving hepatectomy for synchronous or
metachronous colorectal liver metastasis were studied retrospectively.
RESULTS: Fifty-five patients (synchronous group = 35, metachronous group = 20) underwent hepatectomy
for colorectal liver metastases. Besides younger age with male predominance, patients in the synchronous
group had more tumour multinodularity and bilobe liver involvement. They had received less hepatic cura-
tive hepatectomy (81.1% vs. 100%) with a higher rate of peri-operative chemotherapy (91.4% vs. 50%) and post-
operative morbidity (25.7% vs. 0%). However both groups had no statistical significant difference in median
overall survival (OS) and disease free survival (DFS). Inferior OS and DFS were observed in the synchronous
group for patients who had no peri-operative chemotherapy or those showing poor response to chemother-
apy. The most favourable OS is observed in both groups after performing globally curative hepatectomy.
CONCLUSION: Synchronous colorectal liver metastasis is not a poor prognostic factor for survival
when compared with the metachronous metastasis. Globally curative hepatectomy in combination of new
generation of chemotherapy is recommended for the management of resectable colorectal liver metastasis.
[Asian J Surg 2009;32(4):189–97]
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Introduction
About 20–25% of patients have clinically detectable syn-
chronous colorectal liver metastases at the initial diagno-
sis of colorectal cancer and a further 40–50% develop
metachronous liver metastases within 3 years of primary
surgery.1 Although only about 8–23% of colorectal liver
metastases are resectable at the time of initial diagno-
sis,2–4 curative liver resection remains the only treatment
that can offer long-term survival in these two groups of
patients. The reported 5-year survival rates range from
35–40% according to large studies.5–7 However disease
relapse is common even after curative liver resection 
and it occurs in up to 75% of patients.8 In the era of a 
new generation of chemotherapeutic agents such as 
5-fluorouracil/leucovorin with oxaliplatin (FOLFOX), 
5-fluorouracil/leucovorin with irinotecan (FOLFIRI) 
and targeted therapy (e.g. cetuximab, bevacizumab), the
response rates have been increased significantly in recent
years. The improved efficacy of chemotherapy not only
increases patient survival in palliative settings9 but 
also renders the initially unresectable colorectal liver
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metastases resectable in a proportion of patients. Adam
et al in 20044 reported that 12.5% of initially unresectable
metastases can be rendered resectable after a newer gener-
ation of downstaging chemotherapy, and the overall 
5-year survival rate after liver resection can be raised up 
to 33%. Most importantly, the survival benefit of peri-
operative chemotherapy has also extended to eligible and
resected colorectal liver metastases and this was con-
firmed by the recent EORTC 40983 trial.10
Although more and more beneficial evidence of new
chemotherapy for colorectal liver metastasis has been
published in the medical literature, few studies have eval-
uated the differential benefit of new chemotherapy and
liver resection in synchronous versus metachronous liver
metastases.11 The aim of this study is to compare the sur-
vival between groups of patients with synchronous and
metachronous colorectal liver metastasis after liver resection
in the era of new generation of chemotherapeutic agents.
Patients and Methods
From October 2002 to January 2008, a total of 55 patients
undergoing liver resection for colorectal liver metastasis
in a single tertiary referral centre were identified. The
inclusion period started with the introduction of a newer
generation of chemotherapy (FOLFOX or FOLFIRI) into
our centre. These patients were divided into synchronous
group and metachronous group for analysis according 
to the status of liver metastasis. The liver metastasis was
classified as synchronous if the primary colorectal cancer
and hepatic metastasis were discovered at the same time
or during the colectomy, or if the hepatic metastasis 
was discovered before the primary tumour, or within 
3 months after the colectomy without pre-operative
chemotherapy or radiotherapy. Those liver metastases
discovered more than 3 months after the primary cancer
were classified as metachronous tumours.
Tumour resectability was assessed by the hepato-
biliary surgeon, senior radiologist and oncologist at a
joint clinic based on the number, size and extent of the
liver tumour. The aim of the liver resection was to achieve
a macroscopically curative resection with adequate liver
reserve. The decision on peri-operative chemotherapy was
made by the multidisciplinary team based on individual
status. Some of our patients with resectable tumours
received neoadjuvant and adjuvant chemotherapy as they
were recruited as participants of EORTC 40983 trial.10
Pre-operative chemotherapy was also given to patients
with initially unresectable liver metastasis (downstaging
chemotherapy with the intention to shrink the lesions) 
so that they could be considered for hepatectomy at sub-
sequent re-evaluations. For those patients who had re-
ceived pre-operative chemotherapy, the same group of
specialists would assess the response to chemotherapy
and subsequent resectability after three or four cycles of
chemotherapy. Follow-up abdominal computed tomog-
raphy (CT) scans were performed and the response 
to chemotherapy was evaluated according to the WHO
response criteria.12 Postoperative chemotherapy was also
recommended to patients with residual disease after liver
resection. Under normal circumstances, patients had 
to pay for the drug charges of newer chemotherapeutic
agents (FOLFOX, FOLFIRI, cepacitabine, cetuximab,
bevacizumab). It is a widely adopted practice in the Hospital
Authority of Hong Kong.
Patients’ medical records were reviewed retrospectively
and compared for the following data: demographic data,
tumour characteristics, characteristics of hepatectomy,
morbidity and mortality, pre- and post-hepatectomy
chemotherapy, chemotherapy response rate and survival.
All data were recorded in a computerized database to
facilitate subsequent analysis.
Statistical analysis was performed by the Statistical
Package for the Social Sciences (Windows version 15.0;
SPSS Inc, Chicago, IL, USA). The Chi-squared test or
Fisher’s exact test was used for categorical variables,
whereas Mann-Whitney U-test was used for continuous
variables. The Kaplan-Meier method was used in calculat-
ing survival time from the date of first liver resection to
the date of death or the date of last follow-up for those
patients who were still alive. Prognostic factors of survival
were assessed by log-rank test and Cox Regression in uni-
variate and multivariate analysis respectively. Values of 
p of less than 0.05 were considered significant.
Results
Demographics and clinical features
A total of 55 consecutive patients had undergone liver
resection for colorectal liver metastasis during the study
period. The majority (63.6%) of our patients had synchro-
nous colorectal liver metastasis. Compared with the
metachronous group, patients in the synchronous group
were younger (median age, 55.3 vs. 60.0, p = 0.024) and
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were predominantly male (Table 1). Moreover, more
tumour multinodularity and bilobe liver involvement
were observed in the synchronous group. A pre-operative
abdominal CT scan was done for all patients in our study.
Although less pre-operative whole body positron emis-
sion tomography (PET) scans (82.9% vs. 100%, p = 0.056)
were performed in the synchronous group, an additional
CT of the thorax was done for most of the patients (four
out of six) without PET scans. The median number of
liver metastasis for synchronous and metachronous
group were two and one (p = 0.046) and the median maxi-
mal size of tumour in the two groups were 22.5 mm and
33 mm respectively (p = 0.566). There was no statistical
significant difference in ASA classification, the site of 
the primary tumour location and the median carcino-
embryonic antigen (CEA) level at the diagnosis of the 
primary tumour between the two groups (Table 1).
Characteristics of hepatectomy
Thirty-five patients in the synchronous group underwent
37 hepatectomies as two patients in this group had two
separate hepatectomies for recurrent liver metastasis
(Table 2). Another 22 hepatectomies were performed 
for 20 patients in the metachronous group as one patent
had received three separate hepatectomies for the recurrent
disease. All the operations were single-stage hepatectomy.
Both groups had the same median pre-hepatectomy CEA
level (11 ng/mL). Initially, 34.3% of liver metastases in the
synchronous and 10% in the metachronous group were
unresectable (p = 0.058) and the main reason for unre-
sectability was the multinodularity of the tumour (Table
2). Moreover a significant lower rate of hepatic curative
hepatectomy (defined as clear resection margin, irrespec-
tive of extrahepatic disease) could be achieved in the 
synchronous group (81.1% vs. 100%, p = 0.039), but there
■ COLORECTAL LIVER METASTASIS ■
ASIAN JOURNAL OF SURGERY VOL 32 • NO 4 • OCTOBER 2009 191
Table 1. Demographics and clinical features of patients in synchronous and metachronous groups
Synchronous group Metachronous group 
p
(n = 35) (n = 20)
Median age (range) [yr] 55.3 (28–81) 60.0 (49–78) 0.024
Sex (M:F) 24:11 8:12 0.05
ASA classification 0.410
Class 1 24 13
Class 2 11 6
Class 3 0 1
Site of primary colorectal cancer 1.000
Colon 26 15
Rectum 9 5
Dukes’ staging at resection of colorectal cancer* < 0.001
Dukes’ A 0 1
Dukes’ B 0 5
Dukes’ C 0 12
Dukes’ D 35 1
Median CEA level at diagnosis of 14.1(2–3525) 8.9 (3–51) 0.372
colorectal cancer (range) [ng/mL]
Imaging studies for liver metastases
CT abdomen only 35 (100%) 20 (100%)
PET scan 29 (82.9%) 20 (100%) 0.056
Initial liver metastases
Unilobar 20 (57%) 18 (90%) 0.015
Bilobar 15 (43%) 2 (10%) 0.046
Median number of metastases (range) 2 (1–12) 1 (1–2)
Median maximal tumour size
at diagnosis (range) [mm] 22.5 (3–130) 33 (10–130) 0.566
*One patient in the metachronous group had no detailed record for Dukes’ staging.
was no statistically significant difference in the globally
curative resection rate (defined as no residual hepatic 
disease and no extrahepatic metastasis) between the 
two groups (75.7% vs. 95.5%, p = 0.074). A small number 
of patients in the synchronous group with initially 
unresectable liver metastasis received palliative liver resec-
tion after an unfavourable response (no change or pro-
gressive disease) to downstaging chemotherapy. This
surgery was performed in the hope of benefits from
tumour debulking surgery and subsequent palliative
adjuvant chemotherapy. Both groups had a similar pro-
portion of major hepatectomy (≥ 3 Couinaud segments)
of about 41%. During the study period, we did not per-
form synchronous liver resections and colectomies dur-
ing the same operation. Only four laparoscopic minor
hepatectomies (< 3 Couinaud segments) were performed
in this study. Radiofrequency ablation (RFA) was used 
in 25.7% of patients in the synchronous group and 
10% of patients in the metachronous group (p = 0.151) 
and concomitant intra-operative RFA was the most 
commonly used procedure (Table 2). There was no statis-
tically significant difference in the median minimal clear
resection margin for the synchronous and metachronous
group (5 mm vs. 11 mm, p = 0.159).
Morbidity and mortality
There was no operation-associated mortality in our series
(Table 3). All the postoperative complications (25.7%)
were observed in the synchronous group. The majority
were wound infections while one patient had an infected
intra-abdominal collection, which was treated by ultra-
sound-guided trans-abdominal drainage and antibiotics.
The median hospital stays in the synchronous and meta-
chronous groups were 9 and 8 days respectively (p = 0.48).
Peri-operative chemotherapy
Nineteen patients (54.3%) in the synchronous group had
received a median of 6 cycles of pre-hepatectomy chemo-
therapy (range, 2–22). Eleven patients had downstaging
while eight patients had neoadjuvant chemotherapy.
FOLFOX (57.9%) and FOLFIRI (26.35%) were the two
most commonly used initial chemotherapy therapies
(Table 4). The pre-operative chemotherapy response rate
[partial and complete response according to the World
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Table 2. Characteristics of hepatectomy performed for patients with synchronous and metachronous colorectal liver metastases
Characteristics
Synchronous group Metachronous group 
p
(n= 35) (n= 20)
Median pre-hepatectomy CEA level (range) [ng/mL] 11.0 (1–800) 11.0 (2–120) 0.530
Total no. of liver resections performed 37 22 0.235
Patients with
1 hepatectomy 33 19
2 hepatectomies 2 0
3 hepatectomies 0 1
Hepatic curative resection 81.1% (30/37) 100% (22/22) 0.039
Global curative resection 75.7% (28/37) 95.5% (21/22) 0.074
Major hepatectomy (≥ 3 Couinaud segments) 40.5% (15/37) 40.9% (9/22) 1.00
Minor hepatectomy (< 3 Couinaud segments) 59.5% (22/37) 59.1% (13/22)
No. of laparoscopic hepatectomies 3 1
Local ablative treatment 9 3 0.151
Concomitant intra-operative RFA 7 1
Pre-hepatectomy RFA 2 1
Post-hepatectomy RFA 0 1
Patients with initial unresectable liver metastasis 12 2 0.058
Main cause of unresectability
Multinodularity 10 1
Large tumour size 2 1
Median resection margin (range) [mm] 5.0 (0–65) 11.0 (1–60) 0.159
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Table 4. Summary of chemotherapy use in synchronous and metachronous groups
Synchronous group Metachronous group 
(n= 35) (n= 20)
No. of patients with prehepatectomy chemotherapy 19 (54.3%) 1 (5%)
Downstaging 11 1
Neoadjuvant 8 0
Median cycle of chemotherapy (range) 6 (2–22) 5 (4–6)
Usage of 1st line chemotherapy
FOLFOX 11 0
FOLFIRI 5 0
Capecitabine 2 0
5-FUFA 1 1
No. of lines
1 16 0
2 3 1
No. of patients with post-hepatectomy chemotherapy 27 (77.1%) 7 (35%)
Palliative 9 1
Adjuvant 18 6
Median cycle of chemotherapy (range) 2 (2–13) 6 (3–12)
Usage of 1st line chemotherapy
FOLFOX 15 2
FOLFIRI 0 1
5-FUFA 7 4
Capecitabine 4 0
Targeted therapy 1 0
No. of lines
1 18 5
2 7 0
≥ 3 2 2
No. of patients receiving pre-hepatectomy chemotherapy 19 (54.3%) 1 (5%)
Response rate* 57.9 % (11/19) 100% (1/1)
No. of patients receiving post-hepatectomy chemotherapy 27 (77.1%) 7 (35%)
Response rate* 37.0% (10/27) 71.4% (5/7)
Total patients receiving peri-hepatectomy chemotherapy 32 (91.4%) 10 (50%)
Overall response rate* 56.3% (18/32) 60.0% (6/10)
*Response rate is based on partial or complete response to chemotherapy according to WHO response criteria.12
Table 3. Morbidity and mortality for synchronous and metachronous groups
Synchronous group Metachronous group p
No. of patients who developed complications 9 (25.7%) 0 0.02
Non infected collection 2 0
Infected collection with liver failure 1 0
Wound infection 6 0
30 days in-hospital mortality rate 0 0
Median hospital stay (range) [d] 9 (6–31) 8 (4–7) 0.48
Health Organisation (WHO) response criteria] was 57.9%.
Only one patient (5%) in the metachronous group had
received pre-operative chemotherapy. The coverage of
post-hepatectomy chemotherapy was 77.1% in the syn-
chronous and 35% in the metachronous group (Table 4).
A majority of them had received adjuvant rather than pal-
liative postoperative chemotherapy (Table 4). FOLFOX
(55.5%) and 5-fluorouracil/leucovorin (26%) were two
most commonly used first line postoperative chemother-
apy in the synchronous group while 5-fluorouracil/leu-
covorin (71.4%) and FOLFOX (28.6%) were the favourable
first line chemotherapy for the metachronous group. The
postoperative chemotherapy response rates were 37% in
the synchronous and 71.4% in the metachronous group.
Overall the synchronous group had a higher rate of peri-
operative (pre- or post-hepatectomy) chemotherapy when
compared with the metachronous group (91.4% vs. 50%,
p = 0.001) (Table 4). However the overall chemotherapy
response rates (partial or complete response to pre- or
postoperative chemotherapy) were similar in both groups
(synchronous: 56.3%, metachronous: 60%, p = 0.218).
Survival analysis
For unilobar liver metastasis, tumour sizes smaller than
5 cm, resection margins of more than 1 cm, globally cura-
tive resection, and favourable response to chemotherapy
were significant prognostic factors of better overall sur-
vival in univariate analysis (Table 5). In multivariate
analysis, tumours smaller than 5 cm (p = 0.002), global
curative resection (p = 0.013) and a favourable response to
chemotherapy (p = 0.013) were significant independent
prognostic factors.
The median duration of follow up for the synchro-
nous and metachronous groups were 19.3 and 35.4
months respectively (p = 0.964). Although the synchro-
nous group had a shorter median overall survival (OS)
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Table 5. Univariate analysis of prognostic factors of overall survival
Median overall survival (mo) p
Mode of presentation 0.075
Synchronous 29.7
Metachronous 47.7
Location of metastasis 0.003
Bilobed 19.3
Unilateral 54.9
Globally curative resection < 0.001
Yes 48.9
No 17
Pre-hepatectomy CEA 0.119
< 50 42.7
≥ 50 19.3
Size of metastasis 0.02
< 5 cm 48.9
≥ 5 cm 29.7
Resection margin < 0.001
< 1 cm 14.7
≥ 1 cm 39.9
Use of peri-operative chemotherapy 0.822
No 34.6
Yes 39.9
Chemotherapy response 0.001
No chemotherapy/unfavourable response 33.8
Partial/complete response 60.5
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[29.7 (95% confidence interval (CI) 17.0–42.4) vs. 47.4
(95% CI 37.2–57.6) months] and median disease-free 
survival (DSF) [10.0 (95% CI 6.5–13.6) vs. 26.4 (95% 
CI 12.4–40.3) months] when compared with the
metachronous group, both of the observed differences
did not reach a statistically significant level (Figures 1 and
2). Subgroup analysis of survival was also performed in
regard to the response to peri-operative chemotherapy
between the two groups. In the synchronous group,
patients with no chemotherapy or an unfavourable
response to chemotherapy (no change or progressive dis-
ease according to the WHO criteria) had a poorer overall
survival rate [19.3 (95% CI 14.3–24.4) vs. 47.4 (95% CI
25.8–68.9) months, p = 0.014] and disease-free survival
[9.9 (95% CI 6.9–12.8) vs. 17.8 (95% CI 10.9–24.7) months,
p = 0.043] (Figures 3 and 4). On the other hand, for those
patients who showed favourable response (partial or 
complete response) to peri-operative chemotherapy, 
the OS and DFS were similarly good in both groups 
(Figures 5 and 6). Moreover the most favourable median 
overall survival was observed in both groups [synchro-
nous: 44.3 months (95% CI 37.1–51.5), metachronous:
47.4 months (95% CI 37.2–57.6), p = 0.612] after globally
curative hepatectomy for liver metastases (Figure 7).
Discussion
Traditionally, synchronous colorectal liver metastasis 
is regarded as one of the poor prognostic factors 
for survival. Although there is increasing evidence in the
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Figure 1. Kaplan-Meier curves of overall survival in synchronous
and metachronous groups.
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Figure 2. Kaplan-Meier curves of disease-free survival in synchro-
nous and metachronous groups.
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Figure 3. Kaplan-Meier curves of overall survival for patients with
no chemotherapy and poor response to chemotherapy in syn-
chronous and metachronous groups.
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Figure 4. Kaplan-Meier curves of disease-free survival for patients
who had no chemotherapy or those showing a poor response to
chemotherapy in synchronous and metachronous groups.
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medical literature to show the benefit of a newer genera-
tion of chemotherapeutic agents for colorectal liver
metastasis,4,9,10 few studies have evaluated the differen-
tial benefit of new chemotherapy and liver resection in
synchronous versus metachronous liver metastases.11
This is a retrospective study aimed at comparing the sur-
vival between the two groups. Since the duration of fol-
low-up in both groups is relatively short, only the
intermediate survival results are available for comparison
in this study.
Concerning the patients’ demographics and tumour
characteristics, the synchronous group has the character-
istic of younger age with male predominance. Moreover
this group also has more tumour multinodularity and
bilobe liver involvement. As a result, less curative hepatec-
tomy can be achieved and a higher rate of peri-operative
chemotherapy is necessary in this group.
No operation-associated mortality was reported in 
our study. All the postoperative complications were
observed in the synchronous group and the majority of
them were due to minor wound infections. Although the
synchronous group carries all the unfavourable factors
mentioned above, there is no statistically significant dif-
ference observed in the OS and DFS between the two
groups. The most important factor affecting the survival
is the coverage of a newer generation of peri-operative
chemotherapy because the OS and DFS were statistically
inferior in the synchronous group for those patients 
who have no peri-operative chemotherapy or those show-
ing an unfavourable response to chemotherapy (Figures 3
and 4). The most favourable median overall survival is
observed in the two groups after performing globally 
curative liver resection (Figure 7). These results showed that
performing a globally curative hepatectomy and giving 
a newer generation of chemotherapeutic agents in colo-
rectal liver metastases could achieve a survival benefit.
There were several limitations in our study. Firstly,
there was a relatively small sample size in our study. There
was no standardised protocol for chemotherapy and newer
generation chemotherapy could not be afforded by all
patients. However, before the publication of the European
Organization for Research and Treatment of Cancer
(EORTC) 40983 trial in 2008,10 there was no strong evi-
dence to support the use of neoadjuvant and adjuvant
chemotherapy for resectable colorectal liver metastasis.
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Figure 7. Kaplan-Meier curves of overall survival for patients
after globally curative hepatectomy in synchronous and
metachronous groups.
p = 0.421
O
ve
ra
ll 
su
rv
iv
al
 (
%
)
1.0
0.8
0.6
0.4
0.2
0.0
Synchronous
Metachronous
Months
706050403020100
Figure 5. Kaplan-Meier curves of overall survival for patients with
a partial or complete response to chemotherapy in synchronous
and metachronous groups. 
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Figure 6. Kaplan-Meier curves of disease-free survival for patients
with a partial or complete response to chemotherapy in synchro-
nous and metachronous groups.
Moreover the role of adjuvant chemotherapy after cura-
tive hepatectomy is still controversial as there is a lack of
published data on this issue.13 It is understandable that the
metachronous group has a lower rate of peri-operative
chemotherapy because most of the tumours are resectable
and a higher rate of globally curative hepatectomy can 
be achieved in this group.
Conclusion
We conclude that synchronous colorectal liver metastasis
is not a poor prognostic factor for survival when com-
pared with metachronous colorectal liver metastasis.
Resectable synchronous colorectal liver metastasis should
not be an obstacle for aggressive treatment including hepa-
tectomy and peri-operative chemotherapy. The strategy 
of globally curative hepatectomy in combination with 
a new generation of chemotherapy is recommended 
for the management of resectable colorectal liver metas-
tasis. More liberal use of peri-operative chemotherapy
should be considered for both groups in order to optimise
survival.
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